Maze Therapeutics Announces Board and Executive Changes
Ticker: MAZE · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1842295
| Field | Detail |
|---|---|
| Company | Maze Therapeutics, Inc. (MAZE) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $40,000, $30,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Maze Therapeutics shakes up board and exec pay - big changes coming?
AI Summary
On October 6, 2025, Maze Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a departure of directors and the election of new ones, alongside adjustments to compensatory arrangements for certain officers. Specific details regarding the individuals involved and the financial implications of these changes were not elaborated upon in the provided text.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- Maze Therapeutics, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors at Maze Therapeutics?
The filing indicates a departure of directors and the election of new directors, but specific names and the exact number of changes are not detailed in the provided text.
Were there any changes to the executive officers of Maze Therapeutics?
The filing mentions the appointment of certain officers, but does not specify which positions or individuals were affected.
What are the details of the compensatory arrangements for Maze Therapeutics' officers?
The filing notes adjustments to compensatory arrangements for certain officers, but the specifics of these arrangements are not provided in the excerpt.
What is the primary business of Maze Therapeutics, Inc.?
Maze Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When was Maze Therapeutics, Inc. incorporated and where is its principal executive office located?
Maze Therapeutics, Inc. was incorporated in Delaware and its principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California, 94080.
Filing Stats: 863 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-10-06 07:30:16
Key Financial Figures
- $0.001 — ch registered Common Stock - par value $0.001 per share MAZE The Nasdaq Stock Mar
- $40,000 — will receive a pro rata portion of the $40,000 annual retainer for service as a direct
- $30,000 — the year, and a pro rata portion of the $30,000 annual retainer for service as Chairman
Filing Documents
- d84372d8k.htm (8-K) — 25KB
- 0001193125-25-230926.txt ( ) — 140KB
- maze-20251006.xsd (EX-101.SCH) — 3KB
- maze-20251006_lab.xml (EX-101.LAB) — 18KB
- maze-20251006_pre.xml (EX-101.PRE) — 11KB
- d84372d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 By: /s/ Courtney Phillips Courtney Phillips General Counsel and Corporate Secretary